Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 6
Submit an article Journal homepage
662
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis

Reyad DadaDepartment of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia;College of Medicine, Al-Faisal University, Riyadh, Kingdom of Saudi ArabiaCorrespondence[email protected]
,
Jamal ZekriDepartment of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia;College of Medicine, Al-Faisal University, Riyadh, Kingdom of Saudi Arabia
&
Rawan Al SaadiDepartment of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Kingdom of Saudi Arabia
Pages 739-745 | Received 31 Jan 2016, Accepted 07 Apr 2016, Published online: 03 May 2016

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Wouter J. Plattel, Aurore Bergamasco, Fabrizio Trinchese, François Gavini, Nawal Bent-Ennakhil, Athanasios Zomas, Genaro Castillon, Teigna Arredondo-Bisono, Tiffany Cristarella, Yola Moride & Bastian von Tresckow. (2021) Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leukemia & Lymphoma 62:14, pages 3320-3332.
Read now
Mauro Alaibac. (2017) Monoclonal antibodies against cutaneous T-cell lymphomas. Expert Opinion on Biological Therapy 17:12, pages 1503-1510.
Read now

Articles from other publishers (6)

Liana Nikolaenko & Auayporn Nademanee. (2020) Brentuximab vedotin and its use in the treatment of advanced Hodgkin’s lymphoma. Future Oncology 16:29, pages 2273-2282.
Crossref
Reyad Dada & Yazeed Zabani. (2018) Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional experience. Journal of Oncology Pharmacy Practice 25:7, pages 1586-1589.
Crossref
Reyad Dada. (2018) Program death inhibitors in classical Hodgkin’s lymphoma: a comprehensive review. Annals of Hematology 97:4, pages 555-561.
Crossref
Reyad Dada & Jamal Zekri. (2016) Back to life with checkpoint inhibitors in Hodgkin lymphoma. Journal of Oncology Pharmacy Practice 24:2, pages 139-142.
Crossref
Peter H. Wiernik. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 903 937 .
John KuruvillaMichael SavonaRachid BazPaul Morten Mau-SorensenNashat GabrailRamiro GarzonRichard StoneMichael WangLynn SavoiePeter MartinIan FlinnMeagan JacobyThaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham & Martin Gutierrez. (2017) Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 129:24, pages 3175-3183.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.